This paper compared epidermal growth factor receptor (EGFR) mutation detection in cell-free DNA (cfDNA) by three analytical platforms using matched non-small cell lung cancer (NSCLC) tumor specimens as the standard. EGFR mutation detection over the course of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment was also investigated.
Detection of <i>EGFR</i> Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR.
Siggillino A, Ulivi P, Pasini L, Reda MS, Chiadini E, Tofanetti FR, Baglivo S, Metro G, Crinó L, Delmonte A, Minotti V, Roila F, Ludovini V
Purpose
Conclusion
.Using the tumor specimen as the standard, the dPCR-based QuantStudio 3D Digital PCR System had the highest sensitivity and coincidence rate for Del19 followed by PNAclamp and Scorpion-ARMS, but the sensitivity and coincidence rate for L858R and T790M were the same regardless of analysis method. In six patients with T790M negative tumor specimens, T790M mutations were identified in cfDNA using dPCR in addition to (3 patients) or instead of (3 patients) the mutation found in the tumor. The T790M mutations were not observed when analyzed by the other methods which may be attributable to differences in the limit of detection. All other mutations identified in cfDNA corresponded to mutations identified in the tumor specimen. For mutations with low copy number (<1 copy/µL) and high copy number (<1 copy/µL) by dPCR, the detection rates were 11.53% and 63.04%, respectively, by Scorpion-ARMS and 40.38% and 82.6%, respectively, by PNAClamp. The detection rates were also dependent on mutation, with highest detection rates for L858R followed by Del19. Changes in EGFR mutational profile were observed over the course of EGFR-TKI treatment.
Studies (1)
Purpose
This study compared EGFR mutation detection in cfDNA by three analytical platforms using matched NSCLC tumor specimens as the standard. EGFR mutation detection over the course of EGFR-TKI treatment was also investigated. EDTA blood and FFPE tumor specimens were collected from 31 patients treated with EGFR-TKI for pathologically confirmed advanced NSCLC with EGFR activating mutations (no collection details provided). Additional blood specimens were collected on days 8 and 20 of EGFR-TKI treatment. EDTA blood was also collected from 12 healthy patients. DNA was extracted from 10 FFPE sections using the QIAamp DNA FFPE Tissue Kit on the QIAcube Instrument. Blood was centrifuged at 1100 x g for 15 min and then at 1500 x g for 10 min and the isolated plasma was stored at -80°C. cfDNA was isolated from plasma using the QIAamp Circulating Nucleic Acid Kit on a QIAvac instrument and stored at -20°C. EGFR mutations were detected in tumor DNA using the real-time PCR based Scorpion-ARMS PCR Kit on Rotor-Gene Q MDx instrument and the MALD-TOF MS-based MYRIAPOD Lung Status Kit using the MASSArray Sequenom system. EGFR mutations were detected in cfDNA using the real-time PCR-based Scorpion-ARMS EGFR Plasma RGQ PCR Kit and the PNAClamp R EGFR Kits and the digital PCR-based QuantStudio 3D Digital PCR System.
Summary of Findings
Using the tumor tissue, Del19 mutations were found in 19 of 31 patients; six had an L858R mutation; one patient each had an L861Q, L858M, G719C, or S768I mutation; one had a L858R mutation along with a T790M mutation; and one patient had a G719S along with a L833V mutation. The specificity of each of the three methods for the Del19, L858R, and T790M mutations was 100%; however, the sensitivity of the three assays differed. Using the tumor specimen as the standard, the dPCR-based QuantStudio 3D Digital PCR System had the highest sensitivity and coincidence rate for Del19 (85% and 90.62%, respectively), followed by PNAclamp (75% and 84.37%, respectively), and Scorpion-ARMS (45% and 65.62%, respectively). In contrast, the sensitivity and coincidence rate for L858R (42.86% and 78.95%, respectively) and T790M (100% both) were the same regardless of analysis method. In six patients with T790M negative tumor specimens, T790M mutations were identified in cfDNA using dPCR in addition to (3 patients) or instead of (3 patients) the mutation found in the tumor. The T790M mutations were not observed when analyzed by the other methods which could be due to differences in the limit of detection as the limit of detection by dPCR was 0.1% but was 0.5 (del19 and L858R) and 1% (T790M) by the real-time PCR-based assays. All other mutations identified in cfDNA corresponded to mutations identified in the tumor specimen. Of the 104 mutations identified across all patients/methods, 98 (94.23%) were found by dPCR, 65 (62.5%) by PNAclamp, and 35 (33.65%) by Scorpion ARMS. For mutations with low copy number (<1 copy/µL) and high copy number (<1 copy/µL) by dPCR, the detection rates were 11.53% and 63.04% by Scorpion-ARMS, respectively, and 40.38% and 82.6% by PNAClamp, respectively. The detection rates were also dependent on mutation with highest detection rates for L858R followed by Del19. Disease progression occurred in 18 of the 31 patients over the course of EGFR-TKI treatment, 10 of which had T790M with Del19 or L858R, one patient had only T790M, and three had only Del19 or L858R, two patients had the T790M mutation appear during treatment and then disappear again, and the last two patients were negative for T790M at all timepoints.
Biospecimens
FluidPlasmaTissueLungPreservation Types
FormalinFrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNADigital PCRDNAReal-time qPCRDNAMALDI-TOF MSPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Biospecimen location PlasmaTumorBiospecimen Acquisition Time of biospecimen collection 20 days post TKI treatment8 days post TKI treatmentPre-treatmentReal-time qPCR Specific Targeted nucleic acid EGFR Del19EGFR L858REGFR T790MReal-time qPCR Specific Technology platform PNAClamp EGFR-PANAGENEQuantStudio 3D Digital PCR SystemScorpion-ARMS EGFR Plasma RGQ PCR Kit